<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638856</url>
  </required_header>
  <id_info>
    <org_study_id>Rjcyto2531</org_study_id>
    <nct_id>NCT03638856</nct_id>
  </id_info>
  <brief_title>Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy</brief_title>
  <official_title>Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Premenopausal Women Underwent to Diagnostic Hysteroscopy: Double-blind, Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research objective To compare effectiveness of oral Misoprostal for cervical priming in&#xD;
      premenopausal women underwent to diagnostic hysteroscopy Research hypothesis: Null hypothesis&#xD;
      Effectiveness of oral misoprostal for cervical priming in premenopausal women underwent to&#xD;
      diagnostic hysteroscopy is not different from placebo Alternative hypothesis: : Oral&#xD;
      Misoprostal for cervical priming in Premenopausal women underwent to diagnostic hysteroscopy&#xD;
      is better than placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research design Randomized double-blinded placebo-controlled trial. The investigators who&#xD;
      assess the outcomes and the participants do not know Misoprostal group or control group. The&#xD;
      patients are given the random concealed envelop which contains Misoprostal or placebo to take&#xD;
      before hysteroscopy. Surgeon and the investigator whom assess patients do not know group&#xD;
      allocation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2018</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>initial cervical diameter</measure>
    <time_frame>1 year</time_frame>
    <description>The initial hedgar dilator number which can easily insert through cervix</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Abnormal Uterine Bleeding</condition>
  <condition>Chronic Pelvic Pain</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Misoprostal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients were take placebo 2 tab per oral 3 hour before hysteroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 200Mcg Tab</intervention_name>
    <description>patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy</description>
    <arm_group_label>Misoprostal group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Premenopausal women&#xD;
&#xD;
          2. Patients have following indication for diagnosis hysteroscopy&#xD;
&#xD;
               -  Abnormal uterine bleeding&#xD;
&#xD;
               -  Unexplained infertility&#xD;
&#xD;
               -  Recurrent pregnancy loss&#xD;
&#xD;
               -  Chronic pelvic pain&#xD;
&#xD;
               -  Late postpartum hemorrhage&#xD;
&#xD;
          3. Patients provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal women&#xD;
&#xD;
          2. Patients who have contraindication for Misoprostal as following&#xD;
&#xD;
               -  Allergic to Misoprostal&#xD;
&#xD;
               -  Medical illnesses such as cardiovascular diseases, Asthma, Renal disease&#xD;
&#xD;
          3. Patients who have contraindication for Hysteroscopoy as following&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Pelvic inflammatory disease&#xD;
&#xD;
               -  Infection at cervix and vagina&#xD;
&#xD;
               -  Cervical cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>need to evaluation of cervical priming</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical priming</keyword>
  <keyword>Diagnosis hysteroscopy</keyword>
  <keyword>Oral Misoprostal</keyword>
  <keyword>Premenopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

